Literature DB >> 20001611

Lamivudine for the treatment of HIV.

Princy N Kumar1, Parul Patel.   

Abstract

Lamivudine is a nucleoside reverse transcriptase inhibitor that is widely used for the treatment of HIV-1 infection in combination with other antiretrovirals. It is a highly effective agent that can be dosed once or twice daily due to its long intracellular half-life. It also has one of the best tolerability and long-term safety profiles among all antiretroviral agents and continues to be preferred as part of initial or subsequent combination therapy in HIV-infected patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20001611     DOI： 10.1517/17425250903490418

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN： 1742-5255            Impact factor:   4.481


  7 in total

1.  Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

Authors:  Chiara Piana; Wei Zhao; Kimberly Adkison; David Burger; Evelyne Jacqz-Aigrain; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

2.  Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.

Authors:  Sihem Benaboud; Jean Marc Tréluyer; Saik Urien; Stéphane Blanche; Naim Bouazza; Hélène Chappuy; Elisabeth Rey; Emmanuelle Pannier; Ghislaine Firtion; Odile Launay; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

3.  Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.

Authors:  N Jung; C Lehmann; A Rubbert; E Schömig; G Fätkenheuer; P Hartmann; D Taubert
Journal:  Infection       Date:  2012-08-09       Impact factor: 3.553

Review 4.  Prescribing for patients taking antiretroviral therapy.

Authors:  Yasmin Hughes; Louise Tomlins; Tim Usherwood
Journal:  Aust Prescr       Date:  2022-06-01

Review 5.  Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals.

Authors:  Angélica Saraí Jiménez-Osorio; Sinaí Jaen-Vega; Eduardo Fernández-Martínez; María Araceli Ortíz-Rodríguez; María Fernanda Martínez-Salazar; Reyna Cristina Jiménez-Sánchez; Olga Rocío Flores-Chávez; Esther Ramírez-Moreno; José Arias-Rico; Felipe Arteaga-García; Diego Estrada-Luna
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

6.  Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.

Authors:  Teodora Pene Dumitrescu; Kavita Peddiraju; Caifeng Fu; Kalpana Bakshi; Shui Yu; Zhiping Zhang; Allan R Tenorio; Chris Spancake; Shashidhar Joshi; Allen Wolstenholme; Kimberly Adkison
Journal:  Clin Pharmacol Drug Dev       Date:  2019-11-14

Review 7.  Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.

Authors:  Romina Quercia; Carlo-Federico Perno; Justin Koteff; Katy Moore; Cynthia McCoig; Marty St Clair; Daniel Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.